The invention provides new compositions or combinations thereof for the treatment of cancer. More specifically, the invention provides compositions or combinations thereof for cancer treatment including a high-fat diet. Specifically, the high-fat diet is characterized by having approximately 120 g/day or more, or approximately 70% or more of the total daily energy, from fat, based on a real body weight of 50 kg. The diet is preferably a carbohydrate-restricted high-fat diet, and more preferably provided by a ketone formula and/or MCT oil. The dietary therapy by a high-fat diet of the present invention is provided along with surgical treatment, chemotherapy or radiation therapy, or combinations thereof.

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

Disclosed is a composition and method for preventing, ameliorating or treating an EGFR-mutant non-small cell lung cancer including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The composition significantly reduces the level of EGFR in EGFR-mutant non-small cell lung cancer cells, inducing apoptosis. Therefore, the composition is suitable for preventing, ameliorating or treating non-small cell lung cancers in subjects in need thereof. Particularly, the composition is effective in treating and preventing non-small cell lung cancers, which are difficult to effectively treat and prevent with gefitinib or erlotinib. Also disclosed is a composition and method for inhibiting the resistance of a non-small cell lung cancer to an EGFR tyrosine kinase inhibitor including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The inhibitory composition effectively overcomes resistance to EGFR tyrosine kinase inhibitors.

Compositions of a polyunsaturated omega-3 fatty acid such as (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid (EPA) and (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid (DHA) for preventing and/or treating cachexia in a subject are disclosed. The compositions contain a certain amount of the fatty acids as monoacylglycerides. Further, a method of preventing and/or treating cachexia in a subject is disclosed, including administering a composition of EPA and DHA to the subject, wherein at least a part of the fatty acids are provided in monoacylglyceride form.

Compositions of a polyunsaturated omega-3 fatty acid such as (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid (EPA) and (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid (DHA) for preventing and/or treating cachexia in a subject are disclosed. The compositions contain a certain amount of the fatty acids as monoacylglycerides. Further, a method of preventing and/or treating cachexia in a subject is disclosed, including administering a composition of EPA and DHA to the subject, wherein at least a part of the fatty acids are provided in monoacylglyceride form.

Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzymatically degraded royal jelly, gnetum or its extract, and gnetin C.

Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzymatically degraded royal jelly, gnetum or its extract, and gnetin C.